TREATMENT OUTCOME OF NEOADJUVANT THERAPY WITH TCHP REGIMEN IN PATIENTS WITH HER2+ BREAST CANCER AT HANOI ONCOLOGY HOSPITAL
Tạp chí Ung thư học Việt Nam · 15.04.2026
DOI: 10.70755/vnjo.2026.82.8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tạp chí Ung thư học Việt Nam, online erschienen am 15.04.2026. Verfasst von Anh Trần und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Objective
To evaluate the efficacy of neoadjuvant treatment using the TCHP regimen in patients with HER2-positive breast cancer at Hanoi Oncology Hospital.
Materials and Methods: A combined retrospective and prospective cross-sectional descriptive study was conducted on patients with HER2-positive breast cancer treated with the TCHP regimen as neoadjuvant at Hanoi Oncology Hospital from January 2023 to September 2025.
Results
Among 36 enrolled patients, the average age was 48.6 years (range 30–70). There were 20 patients (55.6%) with stage II and 16 patients (44.4%) with stage III disease; 14 patients (38.9%) underwent clip placement before treatment. After 3 cycles, 7 patients (19.4%) achieved clinical complete response; after 6 cycles, this rate doubled to 14 patients (38.9%). The pathological complete response (pCR) rate was achieved in 24 patients (75%). Clinical complete response was a predictive factor for achieving pCR (p < 0.05), while no significant association was found between pCR and age, stage, histological grade, hormone receptor status, or Ki-67. No patients experienced disease progression during treatment. Most adverse events (AEs) were at grade 1–2. The most common grade 3–4 AE was neutropenia (3 patients, 8.3%). No grade 3–4 thrombocytopenia, hepatic, renal, or cardiac toxicities were observed. Two patients (5.6%) experienced grade 1 left ventricular ejection fraction reduction without requiring treatment delay.
Conclusion
The TCHP regimen demonstrates high efficacy with good tolerability and manageable, predictable AEs in patients with HER2+ breast cancer.
Zitieren
APA
Trần, A., Lê, H., & Trần, A. (2026). TREATMENT OUTCOME OF NEOADJUVANT THERAPY WITH TCHP REGIMEN IN PATIENTS WITH HER2+ BREAST CANCER AT HANOI ONCOLOGY HOSPITAL. Tạp chí Ung thư học Việt Nam. https://doi.org/10.70755/vnjo.2026.82.8
Vancouver
Trần A, Lê H, Trần A. TREATMENT OUTCOME OF NEOADJUVANT THERAPY WITH TCHP REGIMEN IN PATIENTS WITH HER2+ BREAST CANCER AT HANOI ONCOLOGY HOSPITAL. Tạp chí Ung thư học Việt Nam. 2026. doi:10.70755/vnjo.2026.82.8
BibTeX
@article{Trn2026,
author = {Trần, Anh and Lê, Hà and Trần, Anh},
title = {TREATMENT OUTCOME OF NEOADJUVANT THERAPY WITH TCHP REGIMEN IN PATIENTS WITH HER2+ BREAST CANCER AT HANOI ONCOLOGY HOSPITAL},
journal = {Tạp chí Ung thư học Việt Nam},
year = {2026},
doi = {10.70755/vnjo.2026.82.8}
}
EUVIMED